Abstract：
The role of human papillomavirus 16 (HPV 16) in esophageal squamous cell carcinoma (ESCC) remains uncertain. Therefore, this study aimed to investigate the prevalence of HPV 16 in patients with ESCC and its impact on theirprognosis. HPV 16 was detected using FISH, and TP53 status was evaluated via immunohistochemistry. The factors influencing prognosis were ananalyzed using the Log-rank test and Cox regression analyses. Among 178 patients with ESCC, 105 and 73 patients were categorized into concurrent chemoradiotherapy (CCRT) and postoperative chemoradiotherapy (POCRT) cohorts, respectively. Among 178 patients, 87 (48.87%) tested positive for HPV 16. Log-rank tests revealed that the overall survival (OS) of patients with ESCC who were HPV 16-positive was longer than that of those who were HPV 16-negative (median OS: 57 months vs. 27 months, p < 0.01**). HPV 16 infection and TP53 mutation status were identified as independent events. The OS of patients with mutant TP53 who were HPV 16-positive was longer than that of those who were HPV 16-negative in both CCRT and POCRT cohorts (p = 0.002** for CCRT cohorts and p = 0.0023** for POCRT cohorts). Conversely, HPV 16 infection had no effect on OS in the wild-type TP53 subgroup (p = 0.13 and 0.052 for CCRT and POCRT cohorts, respectively). As a conclusion, the positive rate of HPV 16 in ESCC in this study was 48.87% (87/178). Among the patients with ESCC who had TP53 mutation, those who were HPV 16-positive exhibited a better prognosis than those who were HPV 16-negative.
摘要：
人乳头瘤病毒16（HPV16）在食管鳞状细胞癌（ESCC）中的作用仍不确定。因此,本研究旨在探讨ESCC患者中HPV16的患病率及其对预后的影响。使用FISH检测HPV16，通过免疫组织化学评估TP53状态。采用Log-rank检验和Cox回归分析影响预后的因素。在178例ESCC患者中，105和73例患者分为同步放化疗（CCRT）和术后放化疗（POCRT）组，分别。在178名患者中，87（48.87%）的HPV16检测呈阳性。Log-rank测试表明，HPV16阳性的ESCC患者的总生存期（OS）长于HPV16阴性的患者（中位OS：57个月与27个月,p<0.01**)。HPV16感染和TP53突变状态被鉴定为独立事件。在CCRT和POCRT队列中，HPV16阳性的突变TP53患者的OS长于HPV16阴性的患者（CCRT队列p=0.002**，POCRT队列p=0.0023**）。相反，HPV16感染对野生型TP53亚组的OS没有影响（对于CCRT和POCRT队列，p=0.13和0.052，分别)。作为结论,本研究ESCC中HPV16的阳性率为48.87%(87/178)。在患有TP53突变的ESCC患者中，HPV16阳性患者的预后优于HPV16阴性患者.
